CD135
| edit |
| Fms-srodna tirozinska kinaza 3 | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dostupne strukture | |||||||||||
| 1RJB, 3QS7, 3QS9 | |||||||||||
| Identifikatori | |||||||||||
| Simboli | FLT3; CD135; FLK-2; FLK2; STK1 | ||||||||||
| Vanjski ID | OMIM: 136351 MGI: 95559 HomoloGene: 3040 GeneCards: FLT3 Gene | ||||||||||
| EC broj | 2.7.10.1 | ||||||||||
| |||||||||||
| Pregled RNK izražavanja | |||||||||||
 | |||||||||||
| podaci | |||||||||||
| Ortolozi | |||||||||||
| Vrsta | Čovek | Miš | |||||||||
| Entrez | 2322 | 14255 | |||||||||
| Ensembl | ENSG00000122025 | ENSMUSG00000042817 | |||||||||
| UniProt | P36888 | Q00342 | |||||||||
| Ref. Sekv. (iRNK) | NM_004119 | NM_010229 | |||||||||
| Ref. Sekv. (protein) | NP_004110 | NP_034359 | |||||||||
| Lokacija (UCSC) | Chr 13: 28.58 - 28.67 Mb | Chr 5: 147.33 - 147.4 Mb | |||||||||
| PubMed pretraga | [1] | [2] | |||||||||
Klaster diferencijacije antigena 135 (CD135, Fms-slična tirozinska kinaza 3, FLT-3, receptorski tip tirozinske proteinske kinaze FLT3, fetusna jetrena kinaza-2, Flk2) protein je koji je kod ljudi kodiran FLT3 genom. FLT3 je citokinski receptor koji pripada klasi III receptorskih tirozinskih kinaza. CD135 je receptor za citokin Flt3 ligand (FLT3L).
On je izražen na površini mnogih hematopoietskih progenitornih ćelija. FLT3 signalizacija je važna za normalno razviće haematopoietskih matičnih i progenitornih ćelija.
FLT3 gen je jedan od najčešće mutiranih gena u akutnoj mijeloidnoj leukemiji (AML).[1]
Reference
- ↑ Yamamoto Y, Kiyoi H, Nakano Y, Suzuki R, Kodera Y, Miyawaki S, Asou N, Kuriyama K, Yagasaki F, Shimazaki C, Akiyama H, Saito K, Nishimura M, Motoji T, Shinagawa K, Takeshita A, Saito H, Ueda R, Ohno R, Naoe T (April 2001). „Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies”. Blood 97 (8): 2434–9. DOI:10.1182/blood.V97.8.2434. PMID 11290608.
Literatura
- Masson K, Rönnstrand L (2009). „Oncogenic signaling from the hematopoietic growth factor receptors c-Kit and Flt3.”. Cell.Signal. 21 (12): 1717–1726. DOI:10.1016/j.cellsig.2009.06.002. PMID 19540337.
- Reilly JT (2003). „FLT3 and its role in the pathogenesis of acute myeloid leukaemia.”. Leuk. Lymphoma 44 (1): 1–7. DOI:10.1080/1042819021000040233. PMID 12691136.
- Kottaridis PD, Gale RE, Linch DC (2003). „Prognostic implications of the presence of FLT3 mutations in patients with acute myeloid leukemia.”. Leuk. Lymphoma 44 (6): 905–13. DOI:10.1080/1042819031000067503. PMID 12854887.
- Gilliland DG (2004). „FLT3-activating mutations in acute promyelocytic leukaemia: a rationale for risk-adapted therapy with FLT3 inhibitors.”. Best practice & research. Clinical haematology 16 (3): 409–17. DOI:10.1016/S1521-6926(03)00063-X. PMID 12935959.
- Drexler HG, Quentmeier H (2005). „FLT3: receptor and ligand.”. Growth Factors 22 (2): 71–3. DOI:10.1080/08977190410001700989. PMID 15253381.
- Naoe T, Kiyoi H (2005). „Normal and oncogenic FLT3.”. Cell. Mol. Life Sci. 61 (23): 2932–8. DOI:10.1007/s00018-004-4274-x. PMID 15583855.
- Sternberg DW, Licht JD (2005). „Therapeutic intervention in leukemias that express the activated fms-like tyrosine kinase 3 (FLT3): opportunities and challenges.”. Curr. Opin. Hematol. 12 (1): 7–13. DOI:10.1097/01.moh.0000147891.06584.d7. PMID 15604885.
- Marcucci G, Mrózek K, Bloomfield CD (2005). „Molecular heterogeneity and prognostic biomarkers in adults with acute myeloid leukemia and normal cytogenetics.”. Curr. Opin. Hematol. 12 (1): 68–75. DOI:10.1097/01.moh.0000149608.29685.d1. PMID 15604894.
- Markovic A, MacKenzie KL, Lock RB (2005). „FLT-3: a new focus in the understanding of acute leukemia.”. Int. J. Biochem. Cell Biol. 37 (6): 1168–72. DOI:10.1016/j.biocel.2004.12.005. PMID 15778081.
- Zheng R, Small D (2006). „Mutant FLT3 signaling contributes to a block in myeloid differentiation.”. Leuk. Lymphoma 46 (12): 1679–87. DOI:10.1080/10428190500261740. PMID 16263569.
- Parcells BW, Ikeda AK, Simms-Waldrip T, et al. (2007). „FMS-like tyrosine kinase 3 in normal hematopoiesis and acute myeloid leukemia.”. Stem Cells 24 (5): 1174–84. DOI:10.1634/stemcells.2005-0519. PMID 16410383.
- Stubbs MC, Armstrong SA (2007). „FLT3 as a therapeutic target in childhood acute leukemia.”. Current drug targets 8 (6): 703–14. DOI:10.2174/138945007780830782. PMID 17584026.
Vanjske veze
- MeSH CD135+Antigen
- p
- r
- u
Receptorske tirozinske kinaze (EC 2.7.10.1) | |||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| |||||||||||||||||||||||||||||||||||||||||||
Nereceptorske tirozinske kinaze (EC 2.7.10.2) | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| |||||||||||||||||||||||
B enzm: 1.1/2/3/4/5/6/7/8/10/11/13/14/15-18, 2.1/2/3/4/5/6/7/8, 2.7.10, 2.7.11-12, 3.1/2/3/4/5/6/7, 3.1.3.48, 3.4.21/22/23/24, 4.1/2/3/4/5/6, 5.1/2/3/4/99, 6.1-3/4/5-6
